Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells
FEBS Open Bio · 2026-08 · 16 (8) · 1602-1614
DOI: 10.1002/2211-5463.70224 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 02.04.2026. Verfasst von Victor Dal Posolo Cinel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence in New Target Discovery, Instituto Butantan, São Paulo, Brazil. Hauptthemen laut MEDLINE: Proteasome Endopeptidase Complex, Melanoma, Genetic Therapy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Amblyomin‐X is a complex Kunitz‐type protease inhibitor from the tick Amblyomma sculptum , with selective pro‐apoptotic effects in tumor cells. While promising when applied exogenously, its large‐scale recombinant production is hindered by structural complexity. This study evaluated the feasibility of expressing Amblyomin‐X via a suicide gene therapy approach and investigated its intracellular fate following gene delivery in human melanoma and nontumoral cell lines. Amblyomin‐X transcripts were equally detected in both cell types; however, protein detection was restricted to nontumoral cells. Thus, we examined the mechanisms underlying Amblyomin‐X degradation in melanoma cells. Mutagenesis of predicted ubiquitination/SUMOylation sites failed to restore protein detection, whereas inhibition of proteasome activity with MG132 restored Amblyomin‐X detection. This confirmed the involvement of a proteasome‐dependent mechanism that limits protein stability and consequently its cytotoxic activity when intracellularly produced in melanoma cells. These findings indicate that proteasomal degradation represents a tumor‐specific barrier to the intracellular expression of Amblyomin‐X in human cancer cells. Addressing this limitation could enable the potent activity of Amblyomin‐X to be harnessed through gene‐based anticancer strategies. Furthermore, these findings advance the understanding of how structurally complex Kunitz‐type proteins with unstructured regions may behave in the context of gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre of Excellence in New Target Discovery, Instituto Butantan, São Paulo, Brazil.
- Molecular Biology, Universidade Federal de São Paulo, Brazil.
- Innovation and Development Laboratory, Instituto Butantan, São Paulo, Brazil.
ORCID-Profile: Victor Dal Posolo Cinel
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Fundação Butantan
Zitieren
APA
Cinel, V. D. P., Pereira, C. D., Lobba, A. R. M., Fessel, M. R., & Chudzinski-Tavassi, A. M. (2026). Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells. FEBS Open Bio, 16(8), 1602-1614. https://doi.org/10.1002/2211-5463.70224
Vancouver
Cinel VDP, Pereira CD, Lobba ARM, Fessel MR, Chudzinski-Tavassi AM. Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells. FEBS Open Bio. 2026;16(8):1602-1614. doi:10.1002/2211-5463.70224
BibTeX
@article{Cinel2026,
author = {Cinel, Victor Dal Posolo and Pereira, Carlos DeOcesano and Lobba, Aline Ramos Maia and Fessel, Melissa Regina and Chudzinski-Tavassi, Ana Marisa},
title = {Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells},
journal = {FEBS Open Bio},
year = {2026},
volume = {16},
number = {8},
pages = {1602--1614},
doi = {10.1002/2211-5463.70224}
}
EUVIMED